#USA #New York #Rosen Law Firm #Securities Class Action #ADMA Biologics

Rosen Law Firm Investigates Securities Claims Against ADMA Biologics

The investment landscape for ADMA Biologics, Inc. (NASDAQ: ADMA) has recently come under scrutiny as Rosen Law Firm, a well-known global firm for investor rights, has initiated an investigation into potential securities class action claims on behalf of its shareholders. This legal scrutiny arises from serious allegations that the company may have disseminated false and misleading information regarding its business operations.

Background of the Investigation

On March 24, 2026, a notable report from Investing.com highlighted alarming claims made by short-seller Culper Research. The report alleged that ADMA Biologics engaged in channel stuffing practices to artificially inflate its revenue patterns. Such allegations could imply significant corporate misconduct that has likely impacted stock performance.

Following the publication of this report, ADMA Biologics shares experienced a steep decline, plummeting by 16.6% in just one day. This drop is reflective of market reactions to potentially damaging information, raising concerns among investors about the integrity of the company's financial disclosures.

Rosen Law Firm aims to protect the rights of investors who may have suffered financial losses due to this situation. They are pushing for shareholders who purchased ADMA Biologics securities to take action, with the hope of joining a proposed contingency fee arrangement for an eventual class action lawsuit. This approach means that affected investors could seek recovery for their losses without upfront costs.

How to Participate in the Class Action

ADMA shareholders who wish to get more involved are encouraged to visit the official page set up by Rosen Law Firm here. Alternatively, individuals can reach out directly via telephone at 866-767-3653 or email at [email protected] for more information about joining the potential class action.

The Importance of Qualified Legal Representation

In the landscape of securities class actions, the Rosen Law Firm emphasizes the need for investors to choose proficient legal counsel. Not all firms that announce investigations have the experience or success rates comparable to those at the Rosen Law Firm. Notably, they have a distinguished history of success in managing significant securities class action lawsuits, having recovered hundreds of millions of dollars for clients over the years.

Their remarkable track record includes being recognized as the number one firm for securities class action settlements in 2017 by ISS Securities Class Action Services. Furthermore, in 2019 alone, they achieved settlements worth over $438 million for investors. Such accomplishments place Rosen Law Firm in a unique position to advocate for affected shareholders effectively.

Conclusion

As the investigation unfolds, ADMA Biologics shareholders should remain vigilant and proactive. The potential for a class action lawsuit may offer a path toward recovering losses incurred due to questionable business practices alleged against the firm. Continuous updates will be provided through various platforms, including LinkedIn, Twitter, and Facebook.

For investors affected by the decline in ADMA Biologics stocks, the time to act is now. By getting involved, shareholders can uphold their rights and pursue the compensation they rightfully deserve amid the ongoing investigation.